Want to see HK:2607 full AI Analyst Report?
Top Page
Shanghai Pharmaceuticals Holding Co
(2607)
Select Model
Select Model
Rating:63Neutral
Price Target:
HK$12.00
▲(4.90% Upside)
Action:Reiterated
Date:10/31/26
The score is driven primarily by financial performance: strong TTM revenue growth is offset by thin and weakening margins, declining ROE, and volatile free cash flow. Valuation is a clear positive with a moderate P/E and high dividend yield, while technicals are neutral-to-slightly weak given price sitting below longer-term moving averages and muted momentum signals.
Positive Factors
Integrated healthcare value chain
Operating across manufacturing, commercialization, distribution, and related healthcare channels gives Shanghai Pharmaceuticals multiple ways to serve hospitals, pharmacies, and healthcare providers. This integrated model can support customer reach, broaden revenue sources, and reinforce its position across the healthcare supply chain over the medium term.
Negative Factors
Thin and declining profitability
The company is growing revenue without maintaining prior profitability levels. Thin and declining net and EBIT margins leave limited protection against cost increases, pricing pressure, or unfavorable mix, while also reducing the earnings benefit that should normally accompany rapid expansion.
Read all positive and negative factors
Positive Factors
Negative Factors
Integrated healthcare value chain
Operating across manufacturing, commercialization, distribution, and related healthcare channels gives Shanghai Pharmaceuticals multiple ways to serve hospitals, pharmacies, and healthcare providers. This integrated model can support customer reach, broaden revenue sources, and reinforce its position across the healthcare supply chain over the medium term.
Read all positive factors
Shanghai Pharmaceuticals Holding Co (2607) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$64.52B
Dividend Yield5.88%
Average Volume (3M)1.68M
Price to Earnings (P/E)11.9
Beta (1Y)0.37
Revenue Growth9.12%
EPS Growth-3.22%
CountryHK
Employees49,608
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)1.38
Shares Outstanding919,072,700
10 Day Avg. Volume1,539,359
30 Day Avg. Volume1,676,611
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)0.50
Price to Sales (P/S)0.13
P/FCF Ratio9.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$16.00Price Target Upside39.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)1.48
Revenue Forecast (FY)HK$296.50B
Shanghai Pharmaceuticals Holding Co Business Overview & Revenue Model
Company Description
Shanghai Pharmaceuticals Holding Co., Ltd., an investment holding company based in Shanghai, People's Republic of China, maintains a robust presence across the pharmaceutical and healthcare industries. Its core activities involve the research, dev...
Shanghai Pharmaceuticals Holding Co Financial Statement Overview
Summary
Income Statement
64
Positive
Balance Sheet
62
Positive
Cash Flow
55
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 290.47B | 283.58B | 275.25B | 260.30B | 231.98B | 215.82B |
| Gross Profit | 30.89B | 30.42B | 30.63B | 30.93B | 30.49B | 28.54B |
| EBITDA | 12.57B | 14.37B | 12.06B | 10.90B | 12.44B | 10.55B |
| Net Income | 5.14B | 5.72B | 4.55B | 3.77B | 5.62B | 5.09B |
Balance Sheet | ||||||
| Total Assets | 241.92B | 233.15B | 221.21B | 211.97B | 198.13B | 163.44B |
| Cash, Cash Equivalents and Short-Term Investments | 42.23B | 43.08B | 44.38B | 40.67B | 37.01B | 22.39B |
| Total Debt | 59.09B | 49.48B | 47.79B | 42.90B | 38.56B | 31.69B |
| Total Liabilities | 148.04B | 143.36B | 137.47B | 131.65B | 120.13B | 104.37B |
| Stockholders Equity | 79.30B | 75.89B | 71.68B | 68.52B | 67.06B | 49.36B |
Cash Flow | ||||||
| Free Cash Flow | 7.22B | 3.83B | 3.43B | 2.26B | 2.06B | 942.55M |
| Operating Cash Flow | 9.50B | 6.15B | 5.83B | 5.23B | 4.74B | 5.06B |
| Investing Cash Flow | -3.14B | -3.98B | 415.98M | -2.49B | -12.47B | -6.02B |
| Financing Cash Flow | -10.64B | -5.65B | -1.86B | 231.85M | 12.14B | 1.57B |
Shanghai Pharmaceuticals Holding Co Technical Analysis
Positive
11.44
Price Trends
11.11
Positive
11.32
Negative
11.26
Negative
Market Momentum
<0.01
Negative
51.11
Neutral
37.18
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2607, the sentiment is Positive. The current price of 11.44 is above the 20-day moving average (MA) of 11.05, above the 50-day MA of 11.11, and above the 200-day MA of 11.26, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 51.11 is Neutral, neither overbought nor oversold. The STOCH value of 37.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2607.
Shanghai Pharmaceuticals Holding Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$4.67B | 11.63 | 7.05% | 4.98% | 6.47% | 8.10% | |
65 Neutral | HK$50.52B | 6.11 | 8.33% | 4.88% | 2.78% | 7.71% | |
63 Neutral | HK$64.52B | 11.88 | 6.64% | 5.88% | 9.12% | -3.22% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | HK$592.92M | 10.83 | 7.70% | 6.26% | 14.25% | 0.83% | |
41 Neutral | HK$360.66M | -5.30 | -273.18% | ― | 5.52% | 56.54% | |
39 Underperform | HK$575.63M | -6.46 | -2.60% | 17.10% | -2.55% | -145.60% |
* Healthcare Sector Average
HK:2607
Shanghai Pharmaceuticals Holding Co
11.11
-0.06
-0.53%
HK:0673
China Health Group
0.26
-0.36
-58.06%
HK:1099
Sinopharm Group Co
16.19
-2.17
-11.84%
HK:1931
IVD Medical Holding Limited
0.36
-5.93
-94.35%
HK:2192
Medlive Technology Co., Ltd.
6.31
-4.03
-38.99%
HK:2289
Charmacy Pharmaceutical Co., Ltd. Class H
5.49
0.38
7.46%
Shanghai Pharmaceuticals Holding Co Corporate Events
Shanghai Pharmaceuticals Issues Unaudited 2026 Third-Quarter Report With Board Assurance
Oct 29, 2026
Shanghai Pharmaceuticals Holding Co., Ltd. has released its unaudited third quarterly report for 2026, prepared under PRC Accounting Standards for Business Enterprises, in compliance with Hong Kong securities disclosure rules. The board, senior ma...
Shanghai Pharmaceuticals Renews Packaging Deal with Wing Fat Printing
Oct 29, 2026
Shanghai Pharmaceuticals Holding Co., Ltd. has renewed its procurement framework agreement with Wing Fat Printing for the period from 1 January 2027 to 31 December 2027. Under the agreement, Wing Fat Group will continue to supply printed packaging...
Shanghai Pharmaceuticals Renews Three-Year Connected Property Leasing Deal
Oct 29, 2026
Shanghai Pharmaceuticals Holding has renewed a three-year property leasing framework agreement with its controlling shareholder, Shanghai Pharmaceutical (Group), under which the group will continue to lease properties from 1 January 2027 to 31 Dec...
Shanghai Pharmaceuticals Sets Board Meeting to Approve Third-Quarter Results
Oct 16, 2026
Shanghai Pharmaceuticals Holding Co., Ltd. has announced that its board will convene on 29 October 2026 to review and approve the group’s third-quarter results for the nine months ended 30 September 2026. The meeting will also clear the way ...
Shanghai Pharmaceuticals Updates Interim Dividend and Tax Details for H Shareholders
Sep 3, 2026
Shanghai Pharmaceuticals Holding has declared an interim ordinary cash dividend of RMB 1 per 10 shares for the six months ended 30 June 2026, equivalent to HKD 1.1663 per 10 shares for H shareholders, with the ex-dividend date set for 16 September...
Shanghai Pharmaceuticals Sets Record Date and Tax Terms for 2026 Interim Dividend
Sep 3, 2026
Shanghai Pharmaceuticals Holding Co., Ltd. has confirmed the record date and payment arrangements for its interim cash dividend for the first half of 2026, declaring RMB1.00 (tax inclusive) for every ten shares. The dividend will be paid on 23 Oct...
Shanghai Pharmaceuticals Posts Strong H1 2026 Profit and Declares Cash Dividend
Aug 27, 2026
Shanghai Pharmaceuticals Holding Co. has released its unaudited interim results for the six months ended 30 June 2026, prepared under Chinese Accounting Standards and reviewed by its board and audit committee. The company’s leadership has co...
Shanghai Pharmaceuticals Announces Interim Cash Dividend for First Half of 2026
Aug 27, 2026
Shanghai Pharmaceuticals Holding Co., Ltd. has announced an interim ordinary cash dividend for the six months ended 30 June 2026, declaring a payout of RMB 1 per 10 shares for the financial year ending 31 December 2026. Key operational dates for H...
Shanghai Pharmaceuticals Sets Board Meeting to Approve 2026 Interim Results and Consider Dividend
Aug 17, 2026
Shanghai Pharmaceuticals Holding Co. has scheduled a board meeting for 27 August 2026 to review and approve the interim results for the six months ended 30 June 2026, covering the performance of the company and its subsidiaries. The board will als...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.